Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Dividend Payments (2016 - 2025)

Historic Preferred Dividend Payments for Cartesian Therapeutics (RNAC) over the last 4 years, with Q2 2025 value amounting to $2.6 million.

  • Cartesian Therapeutics' Preferred Dividend Payments fell 3754.75% to $2.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $6.8 million, marking a year-over-year increase of 6245.25%. This contributed to the annual value of $4.6 million for FY2016, which is 3775.05% down from last year.
  • As of Q2 2025, Cartesian Therapeutics' Preferred Dividend Payments stood at $2.6 million, which was down 3754.75% from $4.2 million recorded in Q2 2024.
  • Cartesian Therapeutics' 5-year Preferred Dividend Payments high stood at $4.2 million for Q2 2024, and its period low was $2.6 million during Q2 2025.